ElectLive
Well-known member
Here's another interesting article that touches on a lot of these issues (cost, risk, etc) written by the well known Dr. Lars Svennson of the Cleveland Clinic: http://www.ccjm.org/content/75/11/802.full
He labels TAVR as a "disruptive" technology...please read his words, but basically a quickly adopted innovation that challenges well established protocol and medical reasoning. One thing he points out that's a bit lost in all of the risk/benefit analysis of current surgical candidate patients is that many patients are now being referred for surgical evaluation for the first time, that wouldn't have been before. Not all are undergoing TAVR, in fact just as many end up with either standard open heart or valvuloplasty, but it's still an important point I think that prior to TAVR many of these "new" patients may have simply been told by a cardiologist "I'm sorry, there's nothing we can do". So now, there's not only new hope, but hope for an expanding patient group as well.
Another interesting point made in that article is that not all pre-surgery risk analysis methods (algorithms and scores) are created equal. In an analysis of around 5,000 PARTNER patients at Cleveland Clinic, the EuroScore method was proven fairly unreliable: observed mortality of 11% versus expected mortality of 26%. In other words, according to EuroScore, the patients were forecast to be much higher risk than they actually were. Of course, this makes me wonder if there's a surgeon in Europe right now writing an article about a study indicating how the Society for Thoracic Surgery (US) algorithm is equally flawed!
As I mentioned, the cost component comes up in the article as well, and let me just paste that directly here:
"While most disruptive technologies are cheaper than the technologies they displace, this may not be the case with percutaneous valve insertion: a standard aortic heart valve costs $2,500 to $6,000, whereas percutaneously delivered valves cost $30,000. The hospital stay may turn out to be a little shorter, which may help control the overall cost. But while the hospital stay after percutaneous insertion may be shorter than for surgical valve replacement (3–5 days vs 5–7 days), percutaneous valve insertion is currently labor-intensive and requires a team of 25 to 30 people, compared with five or six for open repair."
Taking a few steps back, though, I wonder what was written about the first open heart aortic valve replacements half a century ago. Probably a lot of the same stuff, huh? Amazing breakthrough...but high risk, high cost, clinically intensive, etc. Sure, the window of evolution will be different for TAVR, but so long as the same general pathway of development occurs, more and more good news and progress seems a perfectly reasonable expectation, as evidenced by the opinions of many surgeons today. The first open heart aortic valve replacements involved a 25% - 50% mortality risk, yet today the best of the best quote 0.25%. So, 1 in 2 or 1 in 4 versus 1 in 400. Now, that's improvement.
Now, we do already have open heart replacement, of course, it's not like TAVR is the only available option, but for many patients, it actually is. So, for now at least, risk/benefit analysis belongs more to those patients than most of us. TAVR isn't perfect now, nor will it be in the future either, but let's just hope it shows a similar pathway of significant improvement over time...safer, cheaper, easier.
Sure, I understand both sides of the TAVR analysis/argument today, but just wonder instead what will be written about TAVR in 10 years, or 20 years, etc. Who knows, maybe someday there will be a TAVR.org community full of "veterans" assuring "newbies" that is safe and easy, just like we all do here today...
He labels TAVR as a "disruptive" technology...please read his words, but basically a quickly adopted innovation that challenges well established protocol and medical reasoning. One thing he points out that's a bit lost in all of the risk/benefit analysis of current surgical candidate patients is that many patients are now being referred for surgical evaluation for the first time, that wouldn't have been before. Not all are undergoing TAVR, in fact just as many end up with either standard open heart or valvuloplasty, but it's still an important point I think that prior to TAVR many of these "new" patients may have simply been told by a cardiologist "I'm sorry, there's nothing we can do". So now, there's not only new hope, but hope for an expanding patient group as well.
Another interesting point made in that article is that not all pre-surgery risk analysis methods (algorithms and scores) are created equal. In an analysis of around 5,000 PARTNER patients at Cleveland Clinic, the EuroScore method was proven fairly unreliable: observed mortality of 11% versus expected mortality of 26%. In other words, according to EuroScore, the patients were forecast to be much higher risk than they actually were. Of course, this makes me wonder if there's a surgeon in Europe right now writing an article about a study indicating how the Society for Thoracic Surgery (US) algorithm is equally flawed!
As I mentioned, the cost component comes up in the article as well, and let me just paste that directly here:
"While most disruptive technologies are cheaper than the technologies they displace, this may not be the case with percutaneous valve insertion: a standard aortic heart valve costs $2,500 to $6,000, whereas percutaneously delivered valves cost $30,000. The hospital stay may turn out to be a little shorter, which may help control the overall cost. But while the hospital stay after percutaneous insertion may be shorter than for surgical valve replacement (3–5 days vs 5–7 days), percutaneous valve insertion is currently labor-intensive and requires a team of 25 to 30 people, compared with five or six for open repair."
Taking a few steps back, though, I wonder what was written about the first open heart aortic valve replacements half a century ago. Probably a lot of the same stuff, huh? Amazing breakthrough...but high risk, high cost, clinically intensive, etc. Sure, the window of evolution will be different for TAVR, but so long as the same general pathway of development occurs, more and more good news and progress seems a perfectly reasonable expectation, as evidenced by the opinions of many surgeons today. The first open heart aortic valve replacements involved a 25% - 50% mortality risk, yet today the best of the best quote 0.25%. So, 1 in 2 or 1 in 4 versus 1 in 400. Now, that's improvement.
Now, we do already have open heart replacement, of course, it's not like TAVR is the only available option, but for many patients, it actually is. So, for now at least, risk/benefit analysis belongs more to those patients than most of us. TAVR isn't perfect now, nor will it be in the future either, but let's just hope it shows a similar pathway of significant improvement over time...safer, cheaper, easier.
Sure, I understand both sides of the TAVR analysis/argument today, but just wonder instead what will be written about TAVR in 10 years, or 20 years, etc. Who knows, maybe someday there will be a TAVR.org community full of "veterans" assuring "newbies" that is safe and easy, just like we all do here today...